Galmed Pharmaceuticals Ltd. (GLMD) Key Metrics
GLMD valuation today
Trailing 12 months · as of October 2, 2026- Market cap
- $4.9M
- Enterprise value
- −$7.2M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 61.4
- Price / book
- 0.3
- EV / EBITDA
- 0.3
- Dividend yield
- —
- Beta
- 0.67
GLMD key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsGLMD returns How much profit the business earns on the capital it uses.
GLMD financial health Debt, liquidity and how easily interest is covered.
GLMD valuation history
GLMD returns on capital
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
GLMD debt vs cash
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
GLMD price vs earnings per share
GLMD key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $404,402 | — | — | — | — | — | — | — | — | — |
| Enterprise value | −$17.8M | — | — | — | — | — | — | — | — | — |
| Price / book | 0.0 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −2,549.2% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −1,561.6% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $0.75 | $3.19 | $5.46 | $90.00 | $327.60 | $559.87 | $1,040.40 | $1,229.47 | $1,647.07 | $631.87 |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$19.13 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$11.72 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$11.72 | — | — | — | — | — | — | — | — | — |
| Cash per share | $33.69 | — | — | — | — | — | — | — | — | — |
| Book value per share | $29.28 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $29.28 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 539K | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −64.2% | −49.8% | −50.6% | −81.4% | −87.0% | −50.5% | −25.9% | −19.0% | −91.5% | −103.9% |
| Return on invested capital (ROIC) | — | −436.2% | — | — | — | — | — | — | — | — |
| Return on assets (ROA) | −55.5% | −42.8% | −41.7% | −67.2% | −73.0% | −44.4% | −24.4% | −17.9% | −68.2% | −83.3% |
| Return on tangible assets | −55.3% | −40.6% | −41.6% | −107.9% | −88.7% | −54.9% | −26.5% | −10.9% | −62.6% | −103.1% |
| Free cash flow margin | — | — | — | — | — | — | — | −447.2% | — | — |
| Financial health | ||||||||||
| Total debt | — | — | $41,000 | $215,000 | $229,000 | $216,000 | $352,000 | — | — | — |
| Cash & short-term investments | $18.2M | $15.3M | $12.6M | $13.8M | $34.8M | $50.9M | $75.5M | $90.2M | $19.0M | $15.4M |
| Net debt | −$18.2M | −$15.3M | −$12.6M | −$13.6M | −$34.6M | −$50.7M | −$75.1M | −$90.2M | −$19.0M | −$15.4M |
| Debt / equity | — | — | 0.00 | 0.02 | 0.01 | 0.00 | 0.01 | — | — | — |
| Debt / assets | — | — | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 | — | — | — |
| Current ratio | 6.55 | 7.42 | 4.81 | 4.76 | 6.13 | 6.47 | 11.02 | 33.41 | 4.98 | 3.44 |
| Quick ratio | 6.55 | 7.42 | 4.81 | 4.72 | 6.29 | 6.94 | 15.05 | 33.41 | 5.00 | 3.49 |
| Interest coverage | — | -418.5 | -681.1 | -82.1 | -764.7 | -974.5 | -678.1 | -255.1 | -252.3 | -252.0 |
| Working capital | $15.8M | $14.0M | $10.5M | $11.6M | $30.2M | $43.8M | $69.5M | $87.7M | $15.3M | $11.2M |
| Invested capital | −$2.4M | $996,000 | $1.3M | −$147,000 | −$4.1M | −$6.5M | −$5.3M | −$2.3M | −$3.2M | −$4.4M |
| Tangible asset value | $15.8M | $16.3M | $13.9M | $13.4M | $30.5M | $44.2M | $69.9M | $87.9M | $15.8M | $11.1M |
| Net current asset value | $15.8M | $14.0M | $10.5M | $11.6M | $29.9M | $43.6M | $69.1M | $87.7M | $15.3M | $10.4M |
| Graham net-net per share | $28.52 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Share buybacks (net) | — | — | — | — | — | — | $0 | $0 | $0 | $0 |
| Capex / revenue | — | — | — | — | — | — | — | 4.4% | 1.9% | 3.6% |
| Capex / depreciation | — | 0.00 | 0.00 | 0.11 | 0.26 | 1.13 | 0.34 | 0.23 | 0.09 | 0.10 |
| Stock-based compensation / revenue | — | — | — | — | — | — | — | 87.5% | 128.5% | 348.6% |
| R&D / revenue | — | — | — | — | — | — | — | 407.9% | 889.4% | 3,055.9% |
| SG&A / revenue | — | — | — | — | — | — | — | 217.9% | 350.1% | 659.1% |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | — | — | — | — | — | 18.4 | 73.8 | 153.6 |
| Days of inventory on hand | — | — | — | -4,265.3 | -20,592.1 | -148,550.3 | -291,353.4 | — | -4.9 | -5.6 |
| Days payables outstanding | — | 7,007.6 | 26,132.8 | 38,747.4 | 51,782.2 | 61,043.9 | 40,739.2 | — | 74.6 | 57.2 |
| Cash conversion cycle (days) | — | — | — | — | — | — | — | — | -5.6 | 90.9 |
| Receivables turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.79 | 4.94 | 2.38 |
| Payables turnover | — | 0.05 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 4.89 | 6.39 |
| Asset turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.04 | 0.06 | 0.02 |
| Average receivables | $144,500 | $187,000 | $161,000 | $118,000 | $72,500 | $146,000 | $138,500 | $103,000 | $219,500 | $196,500 |
| Average payables | $1.7M | $1.6M | $2.2M | $3.7M | $6.0M | $6.5M | $3.9M | $2.0M | $2.7M | $2.7M |
| Average inventory | — | — | — | −$409,000 | −$2.4M | −$15.9M | −$27.9M | — | −$177,000 | −$262,000 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from GLMD's annual financial statements (latest annual report filed March 31, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
GLMD valuation and financial ratios
Galmed Pharmaceuticals earned a return on equity of −64.2% in fiscal 2025.
See the GLMD income statement, the GLMD chart for price history, or the GLMD stock overview for the latest quote and news.
GLMD key metrics FAQ
What is Galmed Pharmaceuticals's return on equity?
Galmed Pharmaceuticals's return on equity (ROE) was −64.2% in fiscal 2025: net income of -$10.3 million on average shareholders' equity of $16.1 million.
What is Galmed Pharmaceuticals's free cash flow yield?
Galmed Pharmaceuticals generated -$6.3 million of free cash flow in fiscal 2025, a free cash flow yield of −1,561.6% on its market value at year-end ($0.4 million).
What is Galmed Pharmaceuticals's current ratio?
Galmed Pharmaceuticals's current ratio was 6.55 at the end of fiscal 2025: current assets were 6.55 times current liabilities.